Abstract
Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.
Similar content being viewed by others
REFERENCES
Alam, U., Asghar, O., and Azmi, S., Handbook. Clin. Neurol., 2014, vol. 126, pp. 211–222.
Pandey, A., Chawla, S., and Guchhait, P., IUBMB Life, 2015, vol. 67, pp. 506–513.
Aye, T. and Levitsky, L.L., Curr. Opin. Pediatr., 2003, vol. 15, pp. 411–415.
Trandafir, L.M. and Purcarea, M.R., J. Med. Life, 2016, vol. 9, pp. 235–239.
Scheen, A.J., Drugs, 2003, vol. 63, pp. 933–951.
Chiasson, J.-L., Josse, R.G., Gomis, R., et al., Lancet, 2002, vol. 359, pp. 2072–2077.
Wu, H., Liu, J., Lou, Q., et al., Medicine (Baltimore), 2017, vol. 96, p. 7533.
Fosgerau, K. and Hoffmann, T., Drug Discov. Today, 2015, vol. 20, pp. 122–128.
Sintsova, O., Gladkikh, I., Chausova, V., et al., J. Proteomics, 2018, vol. 173, pp. 12–21.
Sintsova, O.V., Monastyrnaya, M.M., Pislyagin, E.A., et al., Russ. J. Bioorg. Chem., 2015, vol. 41, pp. 590–596.
Monastyrnaya, M., Peigneur, S., Zelepuga, E., et al., Mar. Drugs, 2016, vol. 14, p. 229.
Morrison, J.F., Biochim. Biophys. Acta—Enzymology, 1969, vol. 185, pp. 269–286.
Yoon, S.H. and Robyt, J.F., Carbohydr. Res., 2003, vol. 338, pp. 1969–1980.
ACKNOWLEDGMENTS
Molecular weights of the peptides were determined using the equipment of the Far Eastern Center of Molecular Structural Studies (NMR and mass spectrometry) of the Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences.
Funding
This work was supported by the Russian Foundation for Basic Research (project no. 18-38-00389 (preparation of recombinant peptide and determination of Ki)).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflict of interest. This article does not contain any studies involving animals or human participants performed by any of the authors.
Additional information
Translated by M. Batrukova
Rights and permissions
About this article
Cite this article
Sintsova, O.V., Leychenko, E.V., Gladkikh, I.N. et al. Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor. Dokl Biochem Biophys 489, 385–387 (2019). https://doi.org/10.1134/S1607672919060097
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1607672919060097